ASKA Pharmaceutical Holdings Co.,Ltd. [4886.T]
TOKYO, May 25 (Pulse News Wire) – Aska Pharmaceutical Holdings CO.,LTD. (4886.T) announced plans to amend its stock compensation program for executives and introduce a similar plan for outside directors, contingent upon approval at its upcoming annual shareholders' meeting scheduled for June 24, 2026.
Under the revised executive stock compensation program, the total monetary amount payable annually will be up to ¥70 million, with ¥10 million allocated specifically for non-audit committee external directors. Additionally, the company will introduce performance-based restricted stock units, capping the annual payout at ¥70 million. Combined, the total annual payout will not exceed ¥140 million.
The number of ordinary shares to be issued or disposed of annually will also be capped at 70.00 billion shares for service-based restrictions and 70.00 billion shares for performance-based restrictions, totaling up to 140.0 billion shares per year. For outside directors (excluding audit committee members), the company will implement a similar service-based restricted stock unit program, capping the annual monetary amount at ¥10 million and the issuance of ordinary shares at 10,000 shares annually. Directors will contribute the entire monetary amount received as capital towards acquiring the shares, with the subscription price determined based on the closing price of ASKA's ordinary shares on the Tokyo Stock Exchange prior to the board resolution date.
Both programs require the execution of restricted stock allocation agreements prohibiting transfers during a designated restriction period and allowing the company to reclaim shares without payment under certain conditions.
🟢 Confidence: High AI-translated content.